| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2188* | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 517* | 2021 |
| Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global … RK Gupta, MR Jordan, BJ Sultan, A Hill, DHJ Davis, J Gregson, ... The Lancet 380 (9849), 1250-1258, 2012 | 480 | 2012 |
| HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression … RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ... The Lancet infectious diseases 18 (3), 346-355, 2018 | 450 | 2018 |
| Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis J Hemelaar, R Elangovan, J Yun, L Dickson-Tetteh, I Fleminger, S Kirtley, ... The Lancet infectious diseases 19 (2), 143-155, 2019 | 398 | 2019 |
| HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study RL Hamers, CL Wallis, C Kityo, M Siwale, K Mandaliya, F Conradie, ... The Lancet infectious diseases 11 (10), 750-759, 2011 | 349 | 2011 |
| Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ... The Lancet infectious diseases 16 (5), 565-575, 2016 | 302 | 2016 |
| Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ... PLoS medicine 12 (4), e1001810, 2015 | 286 | 2015 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 272 | 2022 |
| Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a … RL Hamers, R Schuurman, KCE Sigaloff, CL Wallis, C Kityo, M Siwale, ... The Lancet infectious diseases 12 (4), 307-317, 2012 | 237 | 2012 |
| Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa KCE Sigaloff, RL Hamers, CL Wallis, C Kityo, M Siwale, P Ive, ME Botes, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 58 (1), 23-31, 2011 | 237 | 2011 |
| Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study H Surendra, IRF Elyazar, BA Djaafara, LL Ekawati, K Saraswati, V Adrian, ... The Lancet Regional Health–Western Pacific 9, 2021 | 230 | 2021 |
| Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies RL Hamers, KCE Sigaloff, AM Wensing, CL Wallis, C Kityo, M Siwale, ... Clinical infectious diseases 54 (11), 1660-1669, 2012 | 200 | 2012 |
| Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa TS Boender, CM Kityo, RS Boerma, RL Hamers, P Ondoa, M Wellington, ... Journal of Antimicrobial Chemotherapy 71 (10), 2918-2927, 2016 | 122 | 2016 |
| Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review RL Hamers, PW Smit, W Stevens, R Schuurman, TF Rinke de Wit Antiviral therapy 14 (5), 619-629, 2009 | 113 | 2009 |
| HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, R Kantor, GU Van Zyl, ... PloS one 10 (12), e0145772, 2015 | 109 | 2015 |
| Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa RL Hamers, KCE Sigaloff, C Kityo, P Mugyenyi, TFR De Wit Current Opinion in HIV and AIDS 8 (1), 19-26, 2013 | 103 | 2013 |
| HIV drug resistance in low-income and middle-income countries RL Hamers, TFR de Wit, CB Holmes The Lancet HIV 5 (10), e588-e596, 2018 | 99 | 2018 |
| Adherence to antiretroviral therapy for HIV in sub‐Saharan Africa and Asia: a comparative analysis of two regional cohorts R Bijker, A Jiamsakul, C Kityo, S Kiertiburanakul, M Siwale, P Phanuphak, ... Journal of the International AIDS Society 20 (1), 21218, 2017 | 96 | 2017 |
| Long-term antiretroviral treatment adherence in HIV-infected adolescents and adults in Uganda: a qualitative study SC Inzaule, RL Hamers, C Kityo, TF Rinke de Wit, M Roura PloS one 11 (11), e0167492, 2016 | 93 | 2016 |
Tobias Rinke de WitProfessor Connected Diagnostics, University of AmsterdamVerified email at aighd.org
